MS drug during pregnancy: what happens to Baby's immune cells?

NCT ID NCT04998812

Completed Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study checked how the multiple sclerosis drug ocrelizumab passes from mother to baby during pregnancy. Researchers measured B cell levels in 70 infants whose mothers took the drug around the time of pregnancy. The goal was to see if the drug affects the baby's immune system at birth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab
What this could lead to: If successful, this could help doctors understand the safety of ocrelizumab during pregnancy and guide treatment decisions for women with MS.
What could go wrong: This is a small, completed observational study, not a treatment trial. It only measures effects, not outcomes, so it cannot prove safety or harm definitively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY ISOLATED SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICALLY ISOLATED SYNDROME MULTIPLE SCLEROSIS

Contacts and locations

Locations

Hopital Pierre Wertheimer - Hopital Neurologique

Bron, 69003, France
Hosp. Clinico San Carlos

Madrid, 28040, Spain
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Hôpital de la Pitié Salpétrière

Paris, 75013, France
Inselspital Bern

Bern, 3010, Switzerland
MultipEL Studies - Institut für klinische Studien

Hamburg, 22179, Germany
St. Josef Hospital GmbH

Bochum, 44791, Germany
The Ken and Ruth Davee department of Neurology

Chicago, Illinois, 60611-4296, United States
University Of Colorado

Aurora, Colorado, 80045, United States
University of California San Francisco

San Francisco, California, 94158, United States
Universitätsspital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.